Phase 1/2 Study of KB-0742 in Solid Tumors
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma (NCT04718675)
KB-0742 (oral CDK9 inhibitor)
The Phase 1/2 trial is enrolling patients with solid tumors or non-Hodgkin lymphoma.
The trial is being conducted in two stages: dose escalation and expansion. The dose-escalation stage is assessing the safety, pharmacokinetic (PK) and pharmacodynamic (PD) profile of KB-0742. The dose and schedule will be further studied in the expansion stage in patients with MYC-amplified solid tumors and other transcriptionally addicted soft-tissue cancers, such as sarcoma and chordoma.
We have sites open in the United States. For a list of sites, click here.